Is this what you call a “breakthrough”?! So far, I am not impressed. The stock decline reflects that. I must be missing something. Management has explaining to do.
When our executives hype the expectations before the release of the data, we lose face. We are the frontline people in oncology and see the offices.
It’s amazing what’s happened here and how this played out. BMS had a huge first mover advantage with PD1 pathway research and commercialization etc...Analysts in 2016 were calling for Opdivo to hit $12B by 2020. Our stock was close to $80. Not only did we let Merck in with our botched 026 trial, but now with 227, it is virtually inevitable that Merck will prevail as the number one IO treatment and certainly the standard in 1L lung...unbelievable. The odds were totally stacked in our favor, and our leaders and researchers managed to screw this up.
So we won’t see any more pictures of Lynelle pointing to her back? Guess not... #six=onebutlungisdone
There once was a bully named Hoch Whose hubris was always no joke She thundered through halls As if she had balls Gripping her 10th Diet Coke But sorry Lynelle Today the stock fell Your regimen finally choked
Time for all you pharma welfare slugs to get a real job. Karma for all those bankrupt cancer patients that believed you
that's right- PFS??? BMS brought a knife to a gunfight with Merck. Game over. Get your resumes together and find another catering gig
See “Vanlev” “Videx EC” the HCV compound disasters and “Baraclude” as lessons that should have been long long learned.
